Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of maintenance mFOLFOX6 + panitumumab vs 5-FU/LV + panitumumab after induction in unresectable KRAS wild-type colorectal cancer
jRCT1080222617Phase 2
- Sponsor
- Takeda
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of panitumumab in colorectal adenocarcinoma and colorectal cancer (CRC) (2 arms), sponsored by Takeda.
02
Drugs
panitumumab
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1080222617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222617.